The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized controlled trial with a cluster of oncologists evaluating of an integrated communication support program for oncologists, caregivers, and patients with rapidly progressing advanced cancer on patient-centered conversation: J-SUPPORT 1704 study.
 
Maiko Fujimori
Honoraria - ReasonWhy; Union of Japanese Scientists and Engineers
Research Funding - Daiwa Securities Health Foundation
 
Ayako Sato
No Relationships to Disclose
 
Takuji Okusaka
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Dainippon Sumitomo Pharma; Eisai; Nihon Servier; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Baxter (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst)
 
Takuhiro Yamaguchi
Stock and Other Ownership Interests - STATCOM
Consulting or Advisory Role - CAC Croit Corporation; Japan Tobacco Inc; Kowa; Ono Pharmaceutical
Speakers' Bureau - Asahi Kasei; Daiichi Sankyo; Nipro Corporation; Takeda; Tsumura & Co.
Research Funding - 3H Clinical Trial; 3H Medi Solution (Inst); A2 Healthcare (Inst); AC Medical (Inst); ClinChoice; Eisai; Facet Biotech (Inst); Hemp Kitchen (Inst); intellim (Inst); Japan Media Corporation (Inst); Japan Tobacco Inc (Inst); Medidata Solutions, Inc (Inst); Medrio (Inst); NIPRO CORPORATION (Inst); Nobori Ltd. (Inst); Ono Pharmaceutical (Inst); Otsuka; Puravida Technologies (Inst); Senju Pharmaceutical; Welby (Inst)
 
Masafumi Ikeda
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Lilly Japan; MSD; Mylan; Novartis; Otsuka; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; EMD Serono; GlaxoSmithKline; Lilly Japan; Micron; Novartis; Ono Pharmaceutical; SERVIER; Takeda
Research Funding - ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nobelpharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)
 
Makoto Ueno
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Merck Serono; MSD; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Astellas Pharma; AstraZeneca (Inst); Chugai Pharma; Delta-Fly Pharma; Eisai (Inst); Incyte (Inst); JPH Clinical Development; Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Masato Ozaka
Honoraria - AstraZeneca; Bayer; EA Pharma; Eisai; MSD; Novartis; Pfizer; Taiho Pharmaceutical; Yakult Honsha
 
Tempei Miyaji
Honoraria - AYUMI; Merck; Pfizer; Takeda
Research Funding - 3H Medi Solution (Inst); A2 Healthcare (Inst); AC Medical (Inst); CAC Croit Corporation (Inst); FMD K&L Japan (Inst); intellim (Inst); Japan Media Corporation (Inst); Japan Tobacco Inc (Inst); Luminary Medical (Inst); Medidata Solutions, Inc (Inst); Medrio (Inst); New Age Trading (Inst); Nipro Corporation (Inst); NOBORI Ltd. (Inst); Ono Pharmaceutical (Inst); Puravida Technologies (Inst); Welby (Inst)
 
Tomoe Mashiko
Employment - Suxac
 
Masako Okamura
No Relationships to Disclose
 
Shinichi Goto
No Relationships to Disclose
 
Yoshiyuki Majima
No Relationships to Disclose
 
Yosuke Uchitomi
No Relationships to Disclose